Markus Sieger – CEO, Polpharma
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights…
Address: Polpharma
Trade Office
Bobrowiecka 6
00-728 Warsaw
Poland,@ Global
Tel: +48 22 364 61 00
Web: http://www.polpharma.pl/en/about-us/
Polpharma SA belongs to the select group of leaders in the pharmaceutical industry in Poland. For 75 years it has enjoyed the trust of patients, doctors and business partners.
Polpharma was established in 1935. In 2000 it was privatised with the participation of exclusively Polish capital. Polpharma’s strength is the combination of many years of experience with modern technologies and the highest standards of management.
Polpharma is currently the largest Polish manufacturer of generic drugs and pharmaceutical substances. It produces a wide range of prescription drugs and drugs used in inpatient care. The company specialises in preparations used in cardiology, gastroenterology and neurology. A significant part of Polpharma’s portfolio contains also OTC drugs.
Polpharma is the majority shareholder in Medana Pharma S.A. from Sieradz, which is the leader in the area of manufacture of paediatric drugs and vitamin preparations in modern forms. Medana’s portfolio includes also dermatological drugs and drugs used in motor organ disorders, as well as dietary supplements.
In July 2010, Polpharma took over from Bioton SA the part of the company dealing with the manufacture and sale of antibiotics.
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights…
Liana Maksyoutova, country manager of Polpharma Ukraine, provides insights into the impressive transformation of the Ukrainian affiliate that she has fostered since inheriting its reins in 2012 and how she…
Polpharma , Poland’s role model and largest Polish manufacturer of drug products and active pharmaceutical ingredients, has pushed the Polish boundaries with the objective to become the fastest growing regional…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and…
Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according…
“Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has…
The general director of Actavis Poland talks about competing in an intense generics market, and the company’s potential in Poland given the country’s 2012 Reimbursement Act. The year 2012 was…
AstraZeneca’s General Manager in Poland discuses AstraZeneca’s strategic realignment to become a highly specialized biotech company after 20 years of presence in Poland. He stresses the importance of the affiliate’s…
Novascon Pharmaceuticals is the second fastest growing company in the OTC/dietary supplement market in Poland. Its founder shares the reasons behind this success, including his strategy to sell their main…
Omega Pharma is a pharmacist champion and one of the fastest growing OTC companies in Poland. Its General Manager in Poland discusses the shift taking place with Pharmacies now becoming…
Schulke Poland’s General Manager wants the affiliate: “to be recognized as a high quality “one stop shop” for hygiene and disinfection. He also comments: “Poland is quite advanced in terms…
The department of innovation and industry under the Ministry of Economy has been preparing a new project called: “Pharmaceutical Industry Mapping.” Its leader hopes: “that the outcome of this exercise…
Bristol-Myers Squibb’s General Manager in Poland stresses the urgent need to allow more innovative drugs to fight against deadly diseases, especially in the field of immune-oncology which he says will:…
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Budget limitations in the Polish vaccine field are a handicap to improving patients’ lives as Sanofi Pasteur General Manager comments: “the National Health Fund’s budget for reimbursement is around EUR…
See our Cookie Privacy Policy Here